LATS2 and colorectal carcinoma: In conclusion, we identified 5’tiRNA-His-GTG as an oncogenic tRNA half in CRC and further uncovered a novel pathway in which hypoxia-induced 5’tiRNA-His-GTG suppresses LATS2, leading to CRC progression.